Key points from article :
Breath Biopsy device is designed to detect cancer hallmarks in molecules exhaled by patients.
1,500 participants being recruited for two-year trial at Addenbrooke’s hospital in Cambridge.
Will be tested with oesophageal, stomach, prostate, kidney, bladder, liver and pancreatic cancers.
Could detect cancer earlier, giving patients the best chance of surviving their disease.
Clinical trial is being run by CRUK in conjunction with Owlstone Medical, which invented the test.
Participants will breathe into the cancer breathalyser for 10 minutes.
Volatile organic compounds (VOCs) collected by the test will be sent to a laboratory for analysis.
Could reduce harm by sparing patients from more invasive tests that they don’t need.
